colorectal cancer

[Cell Reports] Scientists screened a compound library for synergy with low-dose BCL-XL inhibitor A-1155463 to identify pathways that regulated sensitivity to BCL-XL inhibition and revealed that fibroblast growth factor receptor (FGFR)4 inhibition effectively sensitizes to A-1155463 both in vitro and in vivo.

[Trends in Cancer] The authors highlight the importance of stem cell/niche interactions in developing and established colorectal cancer and discuss how these can be modulated to develop novel preventive and therapeutic interventions.

[Journal of Clinical Investigation] Investigators reported that SUMO-specific protease 7 sensed oxidative stress to maintain the CD8+ T cell metabolic state and antitumor functions.

[Nature Cancer] Scientists prioritized the top five synergistic combinations from a large in vitro screen for ex vivo testing on 29 freshly resected human CRC tumors and found that only the combination of mitogen-activated protein kinase kinase and proto-oncogene tyrosine-protein kinase Src inhibition was effective when tested ex vivo.

[Scientific Reports] K3-SPG, a second-generation nanoparticulate Toll-like receptor 9 (TLR9) ligand consisting of K-type CpG oligodeoxynucleotide (ODN) wrapped with schizophyllan, integrated the best of conventional CpG ODNs, making it an ideal cancer immunotherapy adjuvant.

[Cell Death & Disease] PTBP3 knockdown in colorectal cancer cell lines restricted colorectal cancer proliferative capacities in vitro and in vivo.